Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2015-08-27 / 2016 Feb;5(2):e1078057HN Protein of Newcastle Disease Virus Induces Apoptosis Through SAPK/JNK Pathway
/in International Publications, Newcastle Disease Virus /von 2015-08-26 / Appl. Biochem. Biotechnol. 2015 Oct;177(4):940-56Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-08-24 / Technol. Cancer Res. Treat. 2016 10;15(5):NP83-94The therapeutic effect of death: Newcastle disease virus and its antitumor potential
/in International Publications, Newcastle Disease Virus /von 2015-07-26 / Virus Res. 2015 Nov;209:56-66Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
/in International Publications, Newcastle Disease Virus /von 2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-40Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-06-11 / Viruses 2015 Jun;7(6):2980-98Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
/in Breast Cancer, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2015-05-28 / Immunotherapy 2015;7(8):855-60IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity
/in International Publications, Newcastle Disease Virus /von 2015-05-07 / Cell Death Dis 2015 May;6:e1758
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de